Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-09-21 4:55 pm Purchase | 13G | Kura Oncology, Inc. KURA | Flynn James E | 4,374,044 5.89% | 1,991,044 (+83.55%) | View |
| 2023-08-30 08:07 am Purchase | 13G | Invitae Corporation NVTA | Flynn James E | 93,062,106 4.9% | 92,895,440 (+55737.49%) | View |
| 2023-08-14 5:07 pm Sale | 13G | Singular Genomics Systems, Inc. OMIC | Flynn James E | 7,916,655 7.4% | -1,064,216 (-11.85%) | View |
| 2023-06-22 5:46 pm Purchase | 13G | Verastem, Inc. VSTM | Flynn James E | 1,538,461 6.1% | 1,538,461 (New Position) | View |
| 2023-06-09 4:15 pm Sale | 13G | GeneDx Holdings Corp. WGS | Flynn James E | 1,253,895 4.9% | -55,938,206 (-97.81%) | View |
| 2023-05-26 3:09 pm Purchase | 13G | Cabaletta Bio, Inc. CABA | Flynn James E | 2,340,118 5.9% | 1,875,866 (+404.06%) | View |
| 2023-05-23 5:25 pm Sale | 13D | Graybug Vision, Inc. GRAY | Flynn James E | 276,798 4.89% | -100,466 (-26.63%) | View |
| 2023-05-18 4:05 pm Purchase | 13G | Amedisys, Inc. AMED | Flynn James E | 1,794,000 5.51% | 1,794,000 (New Position) | View |
| 2023-05-10 12:51 pm Sale | 13G | Rain Therapeutics Inc. RAIN | Flynn James E | 0 0% | -2,796,261 (Position Closed) | View |
| 2023-05-03 4:58 pm Sale | 13G | Mirum Pharmaceuticals, Inc. MIRM | Flynn James E | 0 0% | -2,032,335 (Position Closed) | View |
| 2023-04-06 4:50 pm Purchase | 13G | Owens & Minor, Inc. OMI | Flynn James E | 4,202,667 5.51% | 4,202,667 (New Position) | View |
| 2023-03-28 09:37 am Sale | 13D | Graybug Vision, Inc. GRAY | Flynn James E | 377,264 6.84% | -1,336,609 (-77.99%) | View |
| 2023-03-27 4:09 pm Sale | 13D | Graybug Vision, Inc. GRAY | Flynn James E | 1,713,873 24.49% | -3,567,840 (-67.55%) | View |
| 2023-03-22 4:17 pm Purchase | 13G | Deciphera Pharmaceuticals, Inc. DCPH | Flynn James E | 4,627,310 6.09% | 2,278,082 (+96.97%) | View |
| 2023-03-16 5:41 pm Purchase | 13D | Larimar Therapeutics, Inc. LRMR | Flynn James E | 16,973,635 39.2% | 10,606 (+0.06%) | View |
| 2023-02-27 5:43 pm Purchase | 13G | Galera Therapeutics, Inc. GRTX | Flynn James E | 2,916,401 4.99% | 2,916,401 (New Position) | View |
| 2023-02-13 5:28 pm Purchase | 13G | Pulmonx Corporation LUNG | Flynn James E | 2,465,263 6.59% | 2,465,263 (New Position) | View |
| 2023-02-13 5:03 pm Sale | 13G | Pulmonx Corporation LUNG | Flynn James E | 0 0% | -2,366,867 (Position Closed) | View |
| 2023-02-10 3:59 pm Sale | 13G | Phathom Pharmaceuticals, Inc. PHAT | Flynn James E | 0 0% | -2,414,897 (Position Closed) | View |
| 2023-02-10 3:57 pm Unchanged | 13G | Terns Pharmaceuticals, Inc. TERN | Flynn James E | 2,851,287 5.76% | 0 (Unchanged) | View |